All Blogs / Health / Diseases & Conditions / Multiple Sclerosis / New


U.K. Launches Program to Raise Awareness of Invisible Illnesses

Signs are appearing outside restrooms in the United Kingdom to advise members of the public that not all disabilities are visible. MORE: Ocrevus’ journey from defiant idea to game-changing treatment According to a report from the BBC, the signs are being posted to help those who have invisible illnesses and to help change public perception. Show More Summary

Small Study Shows Unexpected Reversal of Some MS Symptoms

I don’t usually write about drug studies, especially ones that are tiny and preliminary. But an unexpected result has peaked my interest in this one. Researchers at The University of Queensland in Brisbane, Australia report that half...Show More Summary

Two Women with Different Forms of Multiple Sclerosis Call Ocrevus a Lifesaver

Pamela Arterbridge noticed something was wrong back in 2013 when she woke up one morning, and her legs and feet were tingling. Two years later, Lorraine Lee knew she had a problem when her right leg became extremely fatigued after every workout. Show More Summary

Siponimod Slows Progression of MS Disability, Phase 3 Clinical Trial Shows

Siponimod slows the progression of multiple sclerosis patients’ disability, a Phase 3 clinical trial indicates. The therapy reduced the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS) by 21 percent over three months, researchers said. Show More Summary

Lemtrada Might Outperform Ocrevus in Preventing MS Relapses, Italian Researchers Say

Lemtrada (alemtuzumab) may be more effective in preventing relapses in multiple sclerosis patients than the newly approved Ocrevus (ocrelizumab), according to a study presented April 28 at the American Academy of Neurology (AAN) 2017 Annual Meeting in Boston. Show More Summary

5 Factors That Could Increase Your Autoimmune Disease Risk

It’s estimated that around 24 million people in American suffer from one autoimmune disease or another (often more than one). While the exact cause for most autoimmune diseases is unknown, there are certain aspects which may increase your risk of an autoimmune condition. Show More Summary

MS ‘Miracle’ Emails: Why I’m Over Them

We all get them: emails promoting the next book, the next diet, the new drug, or the next underdog story of the person who “won his battle” with multiple sclerosis (MS). I suspect that because I’ve been writing about life with multiple sclerosis for as long as I have, I get a few more of […]

Crossing MS PATHS — and Taking a Stand for Patient Rights

I knew it was only a matter of time before my MS neurologist would have MS PATHS available to collect clinical data from people who have agreed to participate. MS PATHS is an information- and biological sample-gathering clinical study from Biogen, the leading manufacturer of multiple sclerosis disease-modifying therapies. Show More Summary

MS Patients Seem to Present Earlier Symptoms of Disease Before Diagnosis

Patients with multiple sclerosis (MS) may be developing the disease for up to five years before the first clinical diagnosis is made, a study has found. The study, “Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study,” was published in the journal The Lancet Neurology. Show More Summary

Latest Research Bolsters My Confidence in Using Tecfidera

Many life-affecting decisions are made at the time of an MS diagnosis. Top of the list? The moment you decide your course of treatment. In my case, the decision was entirely up to me. This isn’t typical, I’ve discovered. Many people with MS aren’t given therapeutic options. Show More Summary

Genentech Highlights Rapid Actions of MS Therapy Ocrevus at AAN Meeting

Within the first two months of treatment, Ocrevus (ocrelizumab) reduced relapses in multiple sclerosis (MS) patients by more than half compared to those on Rebif, and almost completely prevented new brain lesions, according to data underscoring the drug’s rapid effects. Show More Summary

Vlogger Explains How She Overcame Her Bladder Issues

Many multiple sclerosis (MS) patients suffer from bladder issues. In this video from Mallery Schuplin, the MS vlogger talks about some of the bladder issues she’s been experiencing and how she has managed to solve them. MORE: Read our seven tips to help you deal with MS-related urinary problems. Show More Summary

39 Years and Counting — on at Least 39 More Great Ones

Last week, I celebrated by 39th birthday. Yes, 39. That’s one year shy of the big 4-0. The last year of my 30s. If life was a rollercoaster ride, I’m about six clicks from the apex; the big plunge awaits me just on the other side. IShow More Summary

My First 270 Days

As I sat home with that broken foot and yet another pair of crutches, I came to the hideous realization that even after my foot healed, I needed to use a cane. My doctors had been warning me for years about the risks I took by walking...Show More Summary

Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio

Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The...Show More Summary

Why the Future of Science Is Crucial to the MS Community

Everything around us, and within us, begins with science. Science is important to the future of humanity’s well-being. Science is what makes the world go around. We all think it’s love, but actually, at its core, love begins with chemistry. Show More Summary

Bioinformatics Approach Identifies Potential Therapies Targeting TNF, a Factor in MS, Other Diseases

Greek researchers have developed a new bioinformatics tool to identify potential therapies for chronic inflammatory diseases. Using this approach, they identified and confirmed the therapeutic potential of two small molecules to target...Show More Summary

Mayo Clinic Neurologist Explains Probable Cause of Multiple Sclerosis

In this video from the Mayo Clinic, neurologist Dr. Dean Wingerchuk explains that multiple sclerosis is a fairly common disease that affects around 400,000 people in the United States. MS tend to strike in early adulthood, with many patients first beginning to experience symptoms of the disease in their 20s and 30s. Show More Summary

Latest Tecfidera and Tysabri Data Suggest Treatments Improve MS Outcomes When Used Early

Real-world data of treatment with Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) in relapsing multiple sclerosis (MS) patients suggest that treatment at early disease stages improves outcomes and prevents disability development. Show More Summary

Copyright © 2015 Regator, LLC